National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 16 of 41
Interferon Responses in Eczema Herpeticum
NCT01429311
Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients
NCT01289717
Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
NCT01266616
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules
NCT01266850
Tenofovir Gel in Pregnancy and Lactation
NCT01136759
Inducing Remission in Type 1 Diabetes With Alefacept
NCT00965458
Phase I STEBVax in Healthy Adults
NCT00974935
Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine
NCT01255410
The Role of Epigenetics in Inner City Asthma
NCT01382836
Antigenic Competition in HIV Preventive Vaccines
NCT01159990
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
NCT01052480
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
NCT01262079
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
NCT01254175
Searching for Persistence of Infection in Lyme Disease
NCT01143558
Screening Protocol for Genetic Diseases of Allergic Inflammation
NCT00852943
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
NCT01172535
Influenza Antiviral DAS181-F03
NCT01173224
Phase IC Study of Safety and PK of SQ109 300mg Daily
NCT01358162
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
NCT01517984
Comparison of Flu Vaccine Doses in Children
NCT01164553
Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines
NCT01086566
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
NCT01183468
Phase I Study of ETEC Vaccine
NCT01147445
Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections
NCT01212042
Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
NCT01095224
2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
NCT01173211
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
NCT01165359
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
NCT01227967
Phase II Tularemia Vaccine Comparison
NCT01150695
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
NCT01221285
Associating Renal Transplantation With the ITN Signature of Tolerance
NCT01516177
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
NCT01175122
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
NCT01116427
ZOSTAVAX® in Renal Transplant Patients
NCT01137669
Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
NCT01212016
EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
NCT01169077
Live Lung Donor Cross-sectional Cohort Study
NCT01524835
Natural History of Severe Allergic Inflammation and Reactions
NCT01164241
Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies
NCT01200823
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
NCT00922259
Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
NCT01103687
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
NCT01072786
Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults
NCT00853255
Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection
NCT01182298
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
NCT01030562
Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants
NCT01139437
Efficacy of Combination Therapies for Gonorrhea Treatment
NCT00926796
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
NCT00912496
Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults
NCT01109329
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
NCT01147042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.